Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
18.25
-0.01 (-0.05%)
Nov 22, 2024, 4:00 PM EST - Market closed
Travere Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 203.45 | 145.24 | 109.46 | 131.84 | 198.32 | 175.34 | Upgrade
|
| Revenue Growth (YoY) | 57.08% | 32.69% | -16.97% | -33.52% | 13.11% | 6.75% | Upgrade
|
| Cost of Revenue | 224.93 | 256.44 | 231.75 | 204.98 | 137.9 | 146.2 | Upgrade
|
| Gross Profit | -21.48 | -111.2 | -122.29 | -73.14 | 60.42 | 29.14 | Upgrade
|
| Selling, General & Admin | 258.21 | 265.54 | 197.52 | 126.28 | 135.8 | 128.95 | Upgrade
|
| Operating Expenses | 258.21 | 265.54 | 197.52 | 126.28 | 135.8 | 128.95 | Upgrade
|
| Operating Income | -279.69 | -376.74 | -319.81 | -199.43 | -75.38 | -99.81 | Upgrade
|
| Interest Expense | -11.19 | -11.33 | -11.01 | -19.68 | -19.05 | -18.83 | Upgrade
|
| Interest & Investment Income | 21.17 | 21.77 | 6.28 | 1.99 | 5 | 10.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.5 | 0.5 | 1.4 | 0.3 | 1.2 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -1.86 | 1.09 | -0.43 | -0.07 | 0.22 | -0.31 | Upgrade
|
| EBT Excluding Unusual Items | -271.06 | -364.72 | -323.58 | -216.88 | -88 | -108.9 | Upgrade
|
| Merger & Restructuring Charges | -12.43 | -11.39 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -15 | Upgrade
|
| Other Unusual Items | - | - | -7.58 | - | -3.66 | 2.95 | Upgrade
|
| Pretax Income | -348.7 | -376.11 | -331.16 | -216.88 | -188.79 | -146.45 | Upgrade
|
| Income Tax Expense | 0.26 | 0.22 | 0.31 | 0.41 | -19.36 | -0.02 | Upgrade
|
| Earnings From Continuing Operations | -348.96 | -376.33 | -331.47 | -217.29 | -169.43 | -146.43 | Upgrade
|
| Earnings From Discontinued Operations | -2.5 | 264.93 | 52.99 | 37.2 | - | - | Upgrade
|
| Net Income | -351.45 | -111.4 | -278.48 | -180.09 | -169.43 | -146.43 | Upgrade
|
| Net Income to Common | -351.45 | -111.4 | -278.48 | -180.09 | -169.43 | -146.43 | Upgrade
|
| Shares Outstanding (Basic) | 77 | 74 | 64 | 60 | 48 | 42 | Upgrade
|
| Shares Outstanding (Diluted) | 77 | 74 | 64 | 60 | 48 | 42 | Upgrade
|
| Shares Change (YoY) | 8.47% | 16.48% | 6.56% | 25.86% | 12.28% | 4.72% | Upgrade
|
| EPS (Basic) | -4.55 | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | Upgrade
|
| EPS (Diluted) | -4.55 | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | Upgrade
|
| Free Cash Flow | -272.34 | -280.69 | -186.48 | -19.89 | -49.51 | -58.41 | Upgrade
|
| Free Cash Flow Per Share | -3.53 | -3.78 | -2.92 | -0.33 | -1.04 | -1.38 | Upgrade
|
| Gross Margin | -10.56% | -76.57% | -111.72% | -55.48% | 30.47% | 16.62% | Upgrade
|
| Operating Margin | -137.48% | -259.40% | -292.17% | -151.27% | -38.01% | -56.92% | Upgrade
|
| Profit Margin | -172.75% | -76.70% | -254.41% | -136.60% | -85.43% | -83.51% | Upgrade
|
| Free Cash Flow Margin | -133.86% | -193.26% | -170.37% | -15.09% | -24.96% | -33.31% | Upgrade
|
| EBITDA | -238.74 | -338.21 | -299.09 | -186.68 | -50.8 | -79.4 | Upgrade
|
| EBITDA Margin | -117.35% | -232.87% | -273.25% | -141.60% | -25.61% | -45.29% | Upgrade
|
| D&A For EBITDA | 40.95 | 38.53 | 20.72 | 12.75 | 24.58 | 20.41 | Upgrade
|
| EBIT | -279.69 | -376.74 | -319.81 | -199.43 | -75.38 | -99.81 | Upgrade
|
| EBIT Margin | -137.48% | -259.40% | -292.17% | -151.27% | -38.01% | -56.92% | Upgrade
|
| Revenue as Reported | 203.45 | 145.24 | 109.46 | 131.84 | 198.32 | 175.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.